Rocephin and Major depression - a phase IV clinical study of FDA data

Summary:

Major depression is reported as a side effect among people who take Rocephin (ceftriaxone sodium), especially for people who are female, 50-59 old, also take Oxycontin, and have Agranulocytosis.

The phase IV clinical study analyzes which people have Major depression when taking Rocephin. It is created by eHealthMe based on reports of 15,458 people who have side effects when taking Rocephin from the FDA, and is updated regularly.

What is Rocephin?

Rocephin has active ingredients of ceftriaxone sodium. It is often used in infection. eHealthMe is studying from 15,665 Rocephin users. Check the latest studies of Rocephin.

What is Major depression?

Major depression (a mood state that goes well beyond temporarily feeling sad or blue. it is a serious medical illness that affects one's thoughts, feelings) is found to be associated with 798 drugs and 1,478 conditions by eHealthMe. Check the latest studies of Major depression.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

15,458 people reported to have side effects when taking Rocephin.
Among them, 18 people (0.12%) have Major depression.

Among these 18 people:

What is the gender of people who have Major depression when taking Rocephin? *

female: 66.67 %
male: 33.33 %

What is the age of people who have Major depression when taking Rocephin? *

What are other drugs people take besides Rocephin? *

What are other side effects people have besides Major depression? *

Fatigue (feeling of tiredness): 14 people, 77.78%
Insomnia (sleeplessness): 13 people, 72.22%
Stress And Anxiety: 13 people, 72.22%
Nausea (feeling of having an urge to vomit): 12 people, 66.67%
Fever: 12 people, 66.67%
Weakness: 11 people, 61.11%
Pain: 10 people, 55.56%
Joint Pain: 10 people, 55.56%
Nausea And Vomiting: 10 people, 55.56%
Chills (felling of cold): 10 people, 55.56%

What are the existing conditions these people have? *

Fibromyalgia (a long-term condition which causes pain all over the body): 8 people, 44.44%
Breast Cancer: 8 people, 44.44%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 8 people, 44.44%
Neuropathy Peripheral (surface nerve damage): 7 people, 38.89%
Pain: 3 people, 16.67%
Lyme Disease (a bacterial infection that is spread to humans by infected ticks): 3 people, 16.67%
Injury: 3 people, 16.67%
Fever: 3 people, 16.67%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 1 person, 5.56%
Depression: 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Rocephin and have Major depression?

- Check whether Major depression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rocephin:

Rocephin (15,665 reports)

Major depression treatments and more:

Major depression (44,987 reports)

Browse all side effects of Rocephin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Major depression:

Major depression (798 drugs)

Browse all the conditions that are associated with Major depression:

Major depression (1,478 conditions)

Related publications that referenced our studies

Agrawal SR, Rajput A, Jain AP, "Leukocytoclastic vasculitis and acute allergic interstitial nephritis following ceftriaxone exposure", Journal of pharmacology & pharmacotherapeutics, 2014 Jan .
Agrawal SR, Rajput A, Jain AP, "Leukocytoclastic vasculitis and acute allergic interstitial nephritis following ceftriaxone exposure", Journal of pharmacology & pharmacotherapeutics, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on ceftriaxone sodium (the active ingredients of Rocephin) and Rocephin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.